Stryker Corporation (SYK)

In the past six months, Stryker reported strong fourth-quarter 2025 results on January 29, 2026, with adjusted EPS of $4.47 and revenue of $7.17 billion, an 11.4% year-over-year increase, driven by robust demand and strong Mako adoption. Stryker also announced an increase in its quarterly dividend to $0.88 per share, paid on January 30, 2026. Despite positive earnings, there has been significant insider selling activity, notably from director Ronda E. Stryker, with sales totaling over $181 million in early February 2026. Potential 2026 tariff pressures, regulatory and macro risks, and competitive pressures in the vascular segment, have been flagged as potential headwinds. Over the past year, the stock has traded within a range of $329.16 to $404.87.

Demand for Stryker's products and services is generally robust, driven by factors such as an aging population in the U.S. and a post-pandemic pickup in surgical procedure volumes. While there is a mention of "typical Q2 seasonality (vacations)" affecting the knee business, the overall trend indicates sustained and strong demand across its diverse product portfolio.

Stryker Corporation is a global medical technology company focused on Orthopaedics, MedSurg, and Neurotechnology and Spine. Its product portfolio aims to improve patient outcomes and enhance surgical efficiency, serving hospitals, healthcare systems, and medical professionals worldwide. Major products include orthopaedic implants, surgical equipment and navigation systems, patient handling and emergency medical equipment, endoscopic and communications systems, and neurosurgical and spinal devices.

Stryker has a significant global presence, serving customers in approximately 75 to over 100 countries. In 2024, 75% of the company's revenues were generated from the United States. The company has shown notable international growth, particularly in Japan, Europe, South Korea, and Canada. Stryker also has a manufacturing footprint in Europe and facilities in locations like Tijuana, Mexico, and Poland, as part of a strategy to diversify production and manage trade risks.

Stryker maintains a strong brand reputation as a global leader in medical technology, driven by its commitment to innovation, quality, and customer service. In 2026, Forbes recognized Stryker on several lists, including "America's Best Companies," "Most Trusted Companies in America," and "America's Best Employers for Engineers." Stryker's reputation has been positively impacted by its strong financial performance and the continued strong adoption of its Mako robotic systems. However, some negative sentiment has been noted, including potential tariff pressures in 2026, regulatory and macro risks, competitive pressures in the vascular segment, and insider selling activity.

Stryker Corp. has a mixed ownership structure. Approximately 39.77% to 77.09% of the company's stock is owned by institutional investors, insiders hold around 4.38% to 5.90% of the stock, while public companies and individual investors own approximately 18.92% to 55.86%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Greenleaf Trust, State Street Corp., Jpmorgan Chase & Co., Price T Rowe Associates Inc /Md/, Geode Capital Management, Llc, and Morgan Stanley.